Pfizer CEO’s Job Is at Risk. A Shot of Discipline Could Help.
As activist Starboard teams up with former Pfizer executives, the pharma giant’s lack of focus is in the spotlight.
Pfizer: A Strong Product Pipeline Could Lead To Significant Upside
Pfizer's stock is poised for growth with strong technical and fundamental indicators, promising pipeline, and Seagen ...
FiercePharma1d
Dupixent takes pharma DTC top spot as Pfizer's COVID drug Paxlovid makes a comeback
AbbVie’s immunology duo Skyrizi and Rinvoq is, in a rare blip this year, not leading the pharma DTC monthly rankings as ...
Is Pfizer a Buy Right Now or a Value Trap?
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Pfizer: A 6% Yielding Ultra SWAN Bargain With Upside Potential
Pfizer (PFE) stock may present opportunities for patient investors. Read how this biotech giant may deliver long-term ...
FiercePharma6d
Amid large cost-cutting drive, Pfizer plans manufacturing layoffs in Ireland
No large pharma company has traversed this decade's ups and downs quite like Pfizer. | No large pharma company has traversed ...
kffhealthnews1d
Out Of The Trash Bin: How Cobenfy’s Unusual Journey Could Change Pharma
Bristol Myers Squibb's schizophrenia drug, which received FDA approval last week, took a long and winding road to get there. Three decades ago, Eli Lilly developed the drug's forerunner, xanomeline, ...